Drugs / CX-801
last change Aug 2024 re-read 3 minutes ago

CX-801

Developed for
cancer
Investigated by
CytomX Therapeutics · Merck Sharp & Dohme LLC

Trials 1

2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06462794 Aug 2024 → Feb 2028 expected cancer CytomX Therapeutics Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CX-801 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06462794 ↗